CARLSBAD, Calif., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the appointment of Sudipto Sur as Chief Information Officer. Dr. Sur will report directly to Samuel D. Riccitelli, Signal's President and Chief Executive Officer.
"We are excited to welcome Dr. Sur who is an experienced healthcare information technologies leader with demonstrated success in making information systems a sustainable competitive advantage as we continue to advance to the next stages of diagnostic development and commercialization," said Mr. Riccitelli. "Dr. Sur represents an expansion to our management team as we continue to execute on our business strategy."
Dr. Sur will be responsible for leading Signal's initiatives in informatics, healthcare data analysis and translating business metrics into actionable corporate strategy. Dr. Sur joins Signal with more than 14 years of experience in business and technology development strategy and data analysis with significant expertise in the definition and development of multidisciplinary products in medical devices, biotechnology, diagnostics, telecommunications, informatics and analytics. Most recently, Dr. Sur was President of Anssur Corp. and Founder and CEO of Miralex Systems from 2007 to 2014, firms that are both involved in modeling, analysis and visualization services for large scale scientific, engineering, marketing and business data as well as in the development of complex engineering systems and algorithms in areas such as medical robotics and unstructured large scale imaging. From 2004 to 2007, he served as Director of R&D for Informatics and Systems for Sequenom. From 2001 to 2004, Dr. Sur was Associate Director for Control Systems and Software for Genoptix, Inc. Dr. Sur also held positions at Able Corporation and OMM Inc.
Dr. Sur commented, "Working with Signal Genetics is an exciting opportunity to join an innovative diagnostics company focused on helping physicians make better-informed decisions on how cancer patients, in particular those with multiple myeloma, are treated. I look forward to working with the team and helping to improve the efficiency and flexibility of health informatics to further advance the Company's development."
Dr. Sur holds a Ph.D. in Control Systems and Robotics from the California Institute of Technology and a B.S. in Mechanical Engineering from the Indian Institute of Technology, Bombay.
About Signal Genetics, Inc.
Signal Genetics, Inc., headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The Company's mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Signal was founded in January 2010 and became the exclusive licensee in its licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, in April 2010.
CONTACT: INVESTOR CONTACT:
The Ruth Group
David Burke
Tel: 646-536-7009
dburke@theruthgroup.com
